Earnings summaries and quarterly performance for ArriVent BioPharma.
Executive leadership at ArriVent BioPharma.
Board of directors at ArriVent BioPharma.
Research analysts covering ArriVent BioPharma.
Recent press releases and 8-K filings for AVBP.
ArriVent BioPharma Provides Updates on Clinical Trials, Financial Position, and New Appointments
AVBP
New Projects/Investments
Guidance Update
Management Change
- ArriVent BioPharma presented final Phase 1b data at the 2025 World Conference on Lung Cancer, demonstrating clinically meaningful outcomes for firmonertinib in EGFR PACC mutant non-small cell lung cancer.
- The company is advancing two global Phase 3 pivotal studies for firmonertinib, with enrollment for the ALPACCA study expected in Q4 2025 and topline data for the FURVENT study projected in early 2026.
- ArriVent reported $305.4 million in cash and investments as of September 30, 2025, supporting operations into mid-2027, and received FDA IND clearance for ARR-217 for gastrointestinal cancers.
Dec 16, 2025, 6:17 PM
ArriVent BioPharma Reports Third Quarter 2025 Financial Results and Pipeline Progress
AVBP
Earnings
New Projects/Investments
Management Change
- ArriVent BioPharma reported a net loss of $34.978 million for the third quarter ended September 30, 2025, and a net loss of $130.764 million for the nine months ended September 30, 2025.
- As of September 30, 2025, the company had $305.4 million in cash and investments, which is anticipated to fund operations into mid-2027.
- The company advanced its pipeline with the presentation of final Phase 1b results for firmonertinib in EGFR PACC mutant NSCLC and received FDA IND clearance for ARR-217, a CDH-17 targeted ADC.
- Upcoming milestones include the expected enrollment of the first patient in the global pivotal Phase 3 trial for PACC mutant NSCLC in Q4 2025 and projected topline data from the global Phase 3 trial in exon 20 insertion mutant NSCLC in early 2026.
- Brent S. Rice was appointed as Chief Commercial Officer in September 2025.
Nov 10, 2025, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more